Targeted Genetics Corporation - Product Pipeline Review - Q4 2010

Date: December 1, 2010
Pages: 61
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: TC5B9414B7EEN
Leaflet:

Download PDF Leaflet

Targeted Genetics Corporation - Product Pipeline Review - Q4 2010
Targeted Genetics Corporation – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Targeted Genetics Corporation – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Targeted Genetics Corporation – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Targeted Genetics Corporation human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Targeted Genetics Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Targeted Genetics Corporation’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Targeted Genetics Corporation’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Targeted Genetics Corporation in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Targeted Genetics Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Targeted Genetics Corporation.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Targeted Genetics Corporation and identify potential opportunities in those areas.
Targeted Genetics Corporation Snapshot
Targeted Genetics Corporation Overview
Key Information
Key Facts
Targeted Genetics Corporation – Research and Development Overview
Key Therapeutic Areas
Targeted Genetics Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Targeted Genetics Corporation – Pipeline Products Glance
Targeted Genetics Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Targeted Genetics Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Targeted Genetics Corporation – Drug Profiles
MYDICAR
  Product Description
  Mechanism of Action
  R&D Progress
tgAAC09
  Product Description
  Mechanism of Action
  R&D Progress
tgAAC94
  Product Description
  Mechanism of Action
  R&D Progress
Huntington’s Disease Program
  Product Description
  Mechanism of Action
  R&D Progress
Targeted Genetics Corporation – Pipeline Analysis
Targeted Genetics Corporation – Pipeline Products by Therapeutic Class
Targeted Genetics Corporation Pipeline Products By Target
Targeted Genetics Corporation – Pipeline Products by Molecule Type
Targeted Genetics Corporation – Recent Pipeline Updates
Targeted Genetics Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
tgAAVCF
Targeted Genetics Corporation – Company Statement
Targeted Genetics Corporation – Locations And Subsidiaries
Head Office
Recent Developments
Nov 15, 2010: Celladon Announces 12-Month Data From Phase II CUPID Clinical Trial Of MYDICAR In Advanced Heart Failure Patients
May 30, 2010: Celladon Reports Phase II Clinical Trial Data Of MYDICAR In Advanced Heart Failure Patients
Apr 28, 2010: Celladon's MYDICAR Meets Primary Endpoint In Phase II Trial For Treatment Of Advanced Heart Failure
Mar 24, 2010: Celladon Receives Notice Of Allowance For Patent Covering MYDICAR
Sep 23, 2009: Celladon's MYDICAR And Small Molecule SERCA2a Studies In Acute and Chronic Heart Failure Selected One Of Windhover’s Top 10 Cardiovascular Programs To Watch
Aug 31, 2009: Celladon Corporation Completes Enrollment Of MYDICAR Phase II Study Of First-In-Human Gene Transfer To Treat Patients With Advanced Heart Failure
May 28, 2009: Celladon Provides Mydicar Program Update Of First-In-Human Trial For Advanced Heart Failure At American Society Of Gene Therapy Annual Meeting
Oct 27, 2008: Targeted Genetics Announces Presentation Of Data From Completed Phase I/II Trial Of tgAAC94 At American College Of Rheumatology
Jun 12, 2008: Targeted Genetics Announces Positive Phase I/II tgAAC94 Data Presented At Annual European Congress Of Rheumatology
Apr 07, 2008: Targeted Genetics Acquires Rights To SiRNA Development Program In Huntington's Disease From Sirna Therapeutics
Financial Deals Landscape
Targeted Genetics Corporation, Deals Volume Summary, 2004 to YTD 2010
Targeted Genetics Corporation, Deals Summary By Region, 2004 to YTD 2010
Targeted Genetics Corporation, Deals Summary, 2004 to YTD 2010
Targeted Genetics Corporation Detailed Deal Summary
Asset Purchase
Genzyme Acquires Patents And Manufacturing Equipment From Targeted Genetics
Acquisition
Chromos Acquires CellExSys From Targeted Genetics
Equity Offering
Targeted Genetics Completes Private Placement Of $19.5 Million
Targeted Genetics Completes Private Placement Of $8.72 Million
Targeted Genetics Completes Private Placement Of $5 Million
Targeted Genetics Completes Private Placement Of $6 Million
Targeted Genetics Completes Public Offering Of $25 Million
Targeted Genetics Enters Into Collaboration With IAVI, CCRI And CHOP
Targeted Genetics Enters Into Collaboration Agreement With Sirna Therapeutics
Targeted Genetics Enters Into Collaboration Agreement With Celladon
Targeted Genetics Extends Collaboration Agreement With IAVI And CCRI
Targeted Genetics Terminates Joint Venture With Elan
Licensing Agreements
Genzyme Enters Into Licensing Agreement With Targeted Genetics
Targeted Genetics Enters Into Licensing Agreement With Sirna Therapeutics
Amsterdam Molecular Therapeutics Enters Into Licensing Agreement With Targeted Genetics
Targeted Genetics Enters Into Licensing Agreement With NIH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 61

LIST OF TABLES

Targeted Genetics Corporation – Pipeline by Therapy Area and Indication, 2010
Targeted Genetics Corporation – Pipeline by Stage of Development, 2010
Targeted Genetics Corporation – Monotherapy Products in Pipeline, 2010
Targeted Genetics Corporation - Phase II, 2010
Targeted Genetics Corporation - Pipeline By Therapeutic Class, 2010
Targeted Genetics Corporation - Pipeline By Target, 2010
Targeted Genetics Corporation – Pipeline By Molecule Type, 2010
Targeted Genetics Corporation – Recent Pipeline Updates, 2010
Targeted Genetics Corporation - Discontinued Pipeline Products, 2010
Targeted Genetics Corporation, Deals Summary, 2004 to YTD 2010
Targeted Genetics Corporation, Deals Summary by Region, 2004 to YTD 2010
Targeted Genetics Corporation, Deals Summary, 2004 to YTD 2010
Genzyme Acquires Patents And Manufacturing Equipment From Targeted Genetics
Chromos Acquires CellExSys From Targeted Genetics
Targeted Genetics Completes Private Placement Of $19.5 Million
Targeted Genetics Completes Private Placement Of $8.72 Million
Targeted Genetics Completes Private Placement Of $5 Million
Targeted Genetics Completes Private Placement Of $6 Million
Targeted Genetics Completes Public Offering Of $25 Million
Targeted Genetics Enters Into Collaboration With IAVI, CCRI And CHOP
Targeted Genetics Enters Into Collaboration Agreement With Sirna Therapeutics
Targeted Genetics Enters Into Collaboration Agreement With Celladon
Targeted Genetics Extends Collaboration Agreement With IAVI And CCRI
Targeted Genetics Terminates Joint Venture With Elan
Genzyme Enters Into Licensing Agreement With Targeted Genetics
Targeted Genetics Enters Into Licensing Agreement With Sirna Therapeutics
Amsterdam Molecular Therapeutics Enters Into Licensing Agreement With Targeted Genetics
Targeted Genetics Enters Into Licensing Agreement With NIH 59

LIST OF FIGURES

Targeted Genetics Corporation – Pipeline by Therapy Area and Indication, 2010
Targeted Genetics Corporation – Pipeline by Stage of Development, 2010
Targeted Genetics Corporation – Monotherapy Products in Pipeline, 2010
Targeted Genetics Corporation – Pipeline By Therapeutic Class, 2010
Targeted Genetics Corporation – Pipeline By Molecule Type, 2010 20

Ask Your Question

Targeted Genetics Corporation - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: